LITERATURE/CLINICAL TRIALS:

 1.     Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf

 2.     Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis: https://mbio.asm.org/content/9/5/e01753-18

 3.     Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV https://www.tandfonline.com/doi/full/10.1038/s41426-018-0063-8

 4.     Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV https://www.mdpi.com/1999-4915/11/1/39/htm   

 5.     Eculizumab (Soliris) in Covid-19 Infected Patients (SOLID-C19) https://clinicaltrials.gov/ct2/show/NCT04288713?term=complement&cond=COVID-19&draw=2&rank=1

 6.     InflaRx starts dosing Covid-19 patients in Europe https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe

 

MOST RELEVANT HYCULT BIOTECH PRODUCTS

  

•           MBL ELISA, HK323

•           MASP-2 ELISA, HK326

•           C3a ELISA, HK354

•           C3c ELISA, HK368

•           C3 ELISA, HK366

•           C5a ELISA, HK349

•           C5 ELISA, HK390

•           TCC ELISA, HK328

•          gC1qR ELISA, HK362

•           C5aR, mAb 20/70, (functional antibody cat.# HM1076 as used is articles 3 and 4)